The Indian Journal of Chest Diseases and Allied Sciences

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  66 (2024)
Volume  65 (2023)
Volume  64 (2022)
Volume  63 (2021)
Volume  62 (2020)
Volume  61 (2019)
Volume  60 (2018)
Volume  59 (2017)
Volume  58 (2016)
Volume  57 (2015)
Volume  56 (2014)
Volume  55 (2013)
Volume  54 (2012)
Volume  53 (2011)
Volume  52 (2010)
Related articles

VOLUME 56 , ISSUE 2 ( April-June, 2014 ) > List of Articles

REVIEW ARTICLE

Acute Exacerbations of Chronic Obstructive Pulmonary Disease: Causes and Impacts

Sunil Kumar Chhabra, Devi Jyoti Dash

Keywords : COPD, Exacerbations, Aetiology, Quality of life, Lung function, Mortality

Citation Information : Chhabra SK, Dash DJ. Acute Exacerbations of Chronic Obstructive Pulmonary Disease: Causes and Impacts. Indian J Chest Dis Allied Sci 2014; 56 (2):93-104.

DOI: 10.5005/ijcdas-56-2-93

License: CC BY-NC 4.0

Published Online: 28-06-2022

Copyright Statement:  Copyright © 2014; The Author(s).


Abstract

Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are recognised clinically as episodes of increased breathlessness and productive cough requiring a more intensive treatment. A subset of patients with this disease is especially prone to such exacerbations. These patients are labelled as ‘frequent exacerbators’. Though yet poorly characterised in terms of host characteristics, including any genetic basis, these patients are believed to represent a distinct phenotype as they have a different natural history with a more progressive disease and a poorer prognosis than those who get exacerbations infrequently. Most exacerbations appear to be associated with infective triggers, either bacterial or viral, although ‘non-infective’ agents, such as air pollution and other irritants may also be important. Susceptibility to exacerbations is determined by multiple factors. Several risk factors have been identified, some of which are modifiable. Chronic obstructive pulmonary disease (COPD) exacerbations are major drivers of health status and patient-centered outcomes, and are a major reason for health care utilisation including hospitalisations and intensive care admissions. These are associated with considerable morbidity and mortality, both immediate and long-term. These episodes have a negative impact on the patient and the disease including high economic burden, increased mortality, worsening of health status, limitation of activity, and aggravation of comorbidities including cardiovascular disease, osteoporosis and neuro-psychiatric complications. Exacerbations also increase the rate of progression of disease, increasing the annual decline in lung function and leading to a poorer prognosis. Evaluation of risk of exacerbations is now included as a major component of the initial assessment of a patient with COPD in addition to the traditionally used lung function parameter, forced expiratory volume in one second (FEV1). Decreasing the risk of exacerbations and their prevention is a major therapeutic goal of management in COPD.

PDF Share
  1. Global Initiative for Obstructive Lung Diseases. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Update 2014. Available at URL: http://www.goldcopd.org. Accessed on March 29, 2014.
  2. British Thoracic Society and Scottish Intercollegiate Guidelines Network (SIGN). British guideline on the management of asthma: a national clinical guideline. (SIGN Publication No. 101). Available at URL: http://www.sign.ac.uk. Accessed on March 29, 2014.
  3. Rodriguez-Roisin R. Towards a consensus definition for COPD exacerbations. Chest 2000;117:398s-401s.
  4. Celli BR, MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932-46.
  5. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196-204.
  6. Ball P. Epidemiology and treatment of chronic bronchitis and its exacerbations. Chest 1995;108:43s-52s.
  7. Sunyer J, Saez M, Murillo C, Castellsague J, Martínez F, Antó JM. Air pollution and emergency room admission for chronic obstructive pulmonary disease. Am J Epidemiol 1993; 137:701-5.
  8. Tseng CM, Chen YT, Ou SM, Hsiao YH, Li SY, Wang SJ, et al. The effect of cold temperature on increased exacerbation of chronic obstructive pulmonary disease: a nationwide study. PLoS One 2013;8:e57066.
  9. Fagon JY, Chastre J, Trouillet JL, Domart Y, Dombret MC, Bornet M, et al. Characterisation of distal bronchial microflora during acute exacerbation of chronic bronchitis. Am Rev Respir Dis 1990;142:1004-8.
  10. Monso E, Ruiz J, Manterola J, Manterola J, Fiz J, Morera JT, et al. Bacterial infection in chronic obstructive pulmonary disease: a study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med 1995;152:1316-20.
  11. Sethi S. Infectious etiology of acute exacerbations of chronic bronchitis. Chest 2000;117:380s-5s.
  12. Martinez FJ, Erb-Downward JR, Huffnagle GB. Significance of the microbiome in chronic obstructive pulmonary disease. Ann Am Thorac Soc 2013;10:s170-9.
  13. Soler N, Torres A, Ewig S, Gonzalez J, Celis R, El-Ebiary M, et al. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. Am J Respir Crit Care Med 1998;157 (5 Pt 1):1498-1505.
  14. Sapey E, Stockley RA. COPD exacerbations. 2. Aetiology. Thorax 2006;61:250-8.
  15. Sethi S. Bacteria in exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2004;1:109-14.
  16. Lin SH, Kuo PH, Hsueh PR, Yang PC, Kuo SH. Sputum bacteriology in hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease in Taiwan with an emphasis on Klebsiella pneumoniae and Pseudomonas aeruginosa. Respirology 2007;12:81-7.
  17. Domenech A, Puig C, Martí S, Santos S, Fernández A, Calatayud L, et al. Infectious etiology of acute exacerbations in severe COPD patients. J Infect 2013;67:516-23.
  18. Sethi S, Wrona C, Grant BJ, Murphy TF. Strain specific immune responses to Haemophilus influenzae in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;169:448-53.
  19. Murphy TF, Brauer AL, Grant BJ, Sethi S. Moraxella catarrhalis in chronic obstructive pulmonary disease: burden of disease and immune response. Am J Respir Crit Care Med 2005;172:195-9.
  20. Murphy TF. Pseudomonas aeruginosa in adults with chronic obstructive pulmonary disease. Curr Opin Pulm Med 2009;15:138-42.
  21. Murphy TF, Brauer AL, Eschberger K, Lobbins P, Grove L, Cai X, et al. Pseudomonas aeruginosa in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008;177:853-60.
  22. Martínez-Solano L, Macia MD, Fajardo A, Oliver A, Martinez JL. Chronic Pseudomonas aeruginosa infection in chronic obstructive pulmonary disease. Clin Infect Dis 2008;47:1526-33.
  23. Pela R, Marchesani F, Agostinelli C, Staccioli D, Cecarini L, Bassotti C, et al. Airways microbial flora in COPD patients in stable clinical conditions and during exacerbations: a bronchoscopic investigation. Monaldi Arch Chest Dis 1998; 53:262-7.
  24. Miravitlles M, Marín A, Monsó E, Vilà S, de la Roza C, Hervás R, et al. Colour of sputum is a marker for bacterial colonisation in chronic obstructive pulmonary disease. Respir Res 2010;11:58.
  25. Calder MA, Schonell ME. Pneumococcal typing and the problem of endogenous or exogenous reinfection in chronic bronchitis. Lancet 1971;1:1156-59.
  26. Groeneveld K, van Alphen L, Eijk PP, Visschers G, Jansen HM, Zanen HC. Endogenous and exogenous re-infections by Haemophilus influenzae in patients with chronic obstructive airways disease: the effect of antibiotic treatment on persistence. J Infect Dis 1990;161:512-71.
  27. Rosell A, Monsó E, Soler N, Torres F, Angrill J, Riise G, et al. Microbiologic determinants of exacerbation in chronic obstructive pulmonary disease. Arch Intern Med 2005; 165:891-7.
  28. Sethi S, Sethi R, Eschberger K, Lobbins P, Cai X, Grant BJ, et al. Airway bacterial concentrations and exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;176:356-61.
  29. Sethi S, Wrona C, Eschberger K, Lobbins P, Cai X, Murphy TF. Inflammatory profile of new bacterial strain exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008;177:491-7.
  30. Patel IS, Seemungal TA, Wilks M, Lloyd-Owen SJ, Donaldson GC, Wedzicha JA. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax 2002;57:759-64.
  31. Wedzicha JA, Donaldson GC. Exacerbations of chronic obstructive pulmonary disease. Respir Care 2003;48:1204-13.
  32. Zhang M, Li Q, Zhang XY, Ding X, Zhu D, Zhou X. Relevance of lower airway bacterial colonization, airway inflammation, and pulmonary function in the stable stage of chronic obstructive pulmonary disease. Eur J Clin Microbiol Infect Dis 2010;29:1487-93.
  33. Varkey JB, Varkey B. Viral infections in patients with chronic obstructive pulmonary disease. Curr Opin Pulm Med 2008; 14:89-94.
  34. Glezen WP, Greenberg SB, Atmar RL, Piedra PA, Couch RB. Impact of respiratory virus infections on persons with chronic underlying conditions. JAMA 2000;283:499-505.
  35. Greenberg SB, Allen M, Wilson J, Atmar RL. Respiratory viral infections in adults with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;162:167-73.
  36. Beckham JB, Cadena A, Lin J, Piedra PA, Glezen WP, Greenberg SB. Respiratory viral infections in patients with chronic obstructive pulmonary disease. J Infect 2005;50:322-30.
  37. Bafadhel M, McKenna S, Terry S, Mistry V, Reid C, Haldar P, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med 2011;184:662-71.
  38. Niewoehner DE, Lokhnygina Y, Rice K, Kuschner WG, Sharafkhaneh A, Sarosi GA, et al. Risk indexes for exacerbations and hospitalizations due to COPD. Chest 2007;131:20-8.
  39. Miravitlles M, Guerrero T, Mayordomo C, Sánchez-Agudo L, Nicolau F, Segú JL. Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression analysis. The EOLO Study Group. Respiration 2000;67:495-501.
  40. Rascon-Aguilar IE, Pamer M, Wludyka P, Cury J, Coultas D, Lambiase LR, et al. Role of gastroesophageal reflux symptoms in exacerbations of COPD. Chest 2006;130:1096-101.
  41. Burgel PR, Nesme-Meyer P, Chanez P, Caillaud D, Carré P, Perez T, et al. Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest 2009;135:975-81.
  42. Anzueto A, Miravitlles M, Ewig S, Legnani D, Heldner S, Stauch K. Identifying patients at risk of late recovery (>/= 8 days) from acute exacerbation of chronic bronchitis and COPD. Respir Med 2012;106:1258-67.
  43. Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010;363:1128-38.
  44. Agusti A, Edwards LD, Rennard SI, MacNee W, Tal-Singer R, Miller BE, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One 2012;7:e37483.
  45. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002;57:847-52.
  46. Hallin R, Koivisto-Hursti UK, Lindberg E, Janson C. Nutritional status, dietary energy intake and the risk of exacerbations in patients with chronic obstructive pulmonary disease (COPD). Respir Med 2006;100:561-67.
  47. Lee SJ, Lee SH, Kim YE, Cho YJ, Jeong YY, Kim HC, et al. Clinical features according to the frequency of acute exacerbation in COPD. Tuberc Respir Dis (Seoul) 2012;72:367-73.
  48. Bahadori K, FitzGerald JM, Levy RD, Fera T, Swiston J. Risk factors and outcomes associated with chronic obstructive pulmonary disease exacerbations requiring hospitalization Canadian Respir J 2009;16:e43-e49.
  49. Donaldson GC, Müllerova H, Locantore N, Hurst JR, Calverley PM, Vestbo J, et al. Factors associated with change in exacerbation frequency in COPD. Respir Res 2013;14:79.
  50. Fan VS, Ramsey SD, Make BJ, Martinez FJ. Physiologic variables and functional status independently predict COPD hospitalizations and emergency department visits in patients with severe COPD. COPD 2007;4:29-39.
  51. Motegi T, Jones RC, Ishii T, Hattori K, Kusunoki Y, Furutate R, et al. A comparison of three multidimensional indices of COPD severity as predictors of future exacerbations. Int J Chron Obstruct Pulmon Dis 2013;8:259-71.
  52. Bertens LC, Reitsma JB, Moons KG, van Mourik Y, Lammers JW, Broekhuizen BD, et al. Development and validation of a model to predict the risk of exacerbations in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2013;8:493-9.
  53. Miravitlles M, Ferrer M, Pont A, Zalacain R, Alvarez-Sala JL, Masa F, et al. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 years follow-up study. Thorax 2004;59:387-95.
  54. Soler-Cataluña JJ, Rodriguez-Roisin R. Frequent chronic obstructive pulmonary disease exacerbators: how much real, how much fictitious? COPD 2010;7:276-84.
  55. Soler JJ, Sanchez L, Latorre M, Alamar J, Roman P, Perpna M. The impact of COPD on hospital resources: the specific burden of COPD patients with high rates of hospitalization. Arch Bronconeumol 2001;37:375-81.
  56. Anzueto A. Impact of exacerbations on COPD. Eur Respir Rev 2010;19:113-8.
  57. Sullivan SD, Ramsey SC, Todd AL, Pharm D. The economic burden in COPD. Chest 2000;117:5S-9S.
  58. Niewoehner DE. The impact of severe exacerbations on quality of life and the clinical course of chronic obstructive pulmonary disease. Am J Med 2006;119(10 Suppl. 1):38-45.
  59. Pasquale MK, Sun SX, Song F, Hartnett HJ, Stemkowski SA. Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly medicare population. Int J Chron Obstruct Pulmon Dis 2012;7:757-64.
  60. Punekar YS, Shukla A, Müllerova H. COPD management costs according to the frequency of COPD exacerbations in UK primary care. Int J Chron Obstruct Pulmon Dis 2014;9:65-73.
  61. Toy EL, Gallagher KF, Stanley EL, Swensen AR, Duh MS. The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a review. COPD 2010;7:214-28.
  62. Connors AF Jr, Dawson NV, Thomas C, Harrell FE Jr, Desbiens N, Fulkerson WJ, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to understand prognoses and preferences for outcomes and risks of treatments). Am J Respir Crit Care Med 1996;154:959-67.
  63. Seemungal TAR, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1418-22.
  64. Spencer S, Jones PW; GLOBE Study Group. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax 2003;58:589-93.
  65. Spencer S, Calverley PMA, Burge PS, Jones PW. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J 2004;23:698-702.
  66. Solem CT, Sun SX, Sudharshan L, Macahilig C, Katyal M, Gao X. Exacerbation-related impairment of quality of life and work productivity in severe and very severe chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2013;8:641-52.
  67. Miravitlles M, García-Sidro P, Fernández-Nistal A, Buendía MJ, Espinosa de los Monteros MJ, Molina J. Course of COPD assessment test (CAT) and clinical COPD questionnaire (CCQ) scores during recovery from exacerbations of chronic obstructive pulmonary disease. Health Qual Life Outcomes 2013;11:147.
  68. Halpin DM, Decramer M, Celli B, Kesten S, Liu D, Tashkin DP. Exacerbation frequency and course of COPD. Int J Chron Obstruct Pulmon Dis 2012;11:653-61.
  69. Tashkin DP. Variations in FEV1 decline over time in chronic obstructive pulmonary disease and its implications. Curr Opin Pulm Med 2013;19:116-24.
  70. Seemungal TAR, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:1608-13.
  71. Kanner RE, Anthonisen NR, Connett JE. Lower respiratory illnesses promote FEV1 decline in current smokers but not exsmokers with mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:358-64.
  72. Anzueto A, Leimer I, Kesten S. Impact of frequency of COPD exacerbations on pulmonary function, health status and clinical outcomes. Int J Chron Obstruct Pulmon Dis 2009;4:245-51.
  73. Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008;178:332-8.
  74. Makris D, Moschandreas J, Damianaki A, Ntaoukakis E, Siafakas NM, Milic Emili J, et al. Exacerbations and lung function decline in COPD: new insights in current and exsmokers. Respir Med 2007;101:1305-12.
  75. Roberts CM, Lowe D, Bucknall CE, Ryland I, Kelly Y, Pearson MG. Clinical audit indicators of outcome following admission to hospital with acute exacerbation of chronic obstructive pulmonary disease. Thorax 2002;57:137-41.
  76. Soler-Cataluna JJ, Martýnez-Garćýa MA, Roman Sanchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005;60:925-31.
  77. Soler-Cataluna JJ, Martýnez-Garcýa MA, Sanchez L, Perpina M, Roman P. Severe exacerbations and BODE index: two independent risk factors for death in male COPD patients. Respir Med 2009;103:692-99.
  78. Suissa S, Dell'Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax 2012;67:957-63.
  79. Almagro P, SalvadóM, Garcia-Vidal C, Rodríguez-Carballeira M, Cuchi E, Torres J, et al. Pseudomonas aeruginosa and mortality after hospital admission for chronic obstructive pulmonary disease. Respiration 2012;84:36-43.
  80. Slenter RH, Sprooten RT, Kotz D, Wesseling G, Wouters EF, Rohde GG. Predictors of 1-year mortality at hospital admission for acute exacerbations of chronic obstructive pulmonary disease. Respiration 2013;85:15-26.
  81. Beeh KM, Glaab T, Stowasser S, Schmidt H, Fabbri LM, Rabe KF, et al. Characterisation of exacerbation risk and exacerbator phenotypes in the POET-COPD trial. Respir Res 2013;29:116.
  82. Bustamante-Fermosel A, De Miguel-Yanes JM, Duffort-Falco M, et al. Mortality-related factors after hospitalization for acute exacerbation of chronic obstructive pulmonary disease: the burden of clinical features. Am J Emergency Med 2007;25:515-22.
  83. Zvezdin B, Milutinov S, Kojicic M, Hadnadjev M, Hromis S, Markovic M, et al. A postmortem analysis of major causes of early death in patients hospitalized with COPD exacerbation. Chest 2009;136:376-80.
  84. Groenewegen KH, Schols AM, Wouters EF. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest 2003;124:459-67.
  85. Spruit MA, Gosselink R, Troosters T, Kasran A, Gayan- Ramirez G, Bogaerts P, et al. Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-I. Thorax 2003;58:752-6.
  86. Donaldson GC, Wilkinson TM, Hurst JR, Perera WR, Wedzicha JA. Exacerbations and time spent outdoors in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;171:446-52.
  87. Pitta F, Troosters T, Probst VS, Spruit MA, Decramer M, Gosselink R. Physical activity and hospitalization for exacerbation of COPD. Chest 2006;129:536-44.
  88. Borges RC, Carvalho CR. Physical activity in daily life in Brazilian COPD patients during and after exacerbation. COPD 2012;9:596-602.
  89. Hodgev VA, Kostianev SS, Marinov BA. Correlation of frequency of exacerbations with the BODE index in COPD patients. Folia Med (Plovdiv) 2006;48:18-22.
  90. Cote CG, Dordelly LJ, Celli BR. Impact of COPD exacerbations on patient-centered outcomes. Chest 2007;131: 696-704.
  91. Brekke PH, Omland T, Smith P, Søyseth V. Underdiagnosis of myocardial infarction in COPD: Cardiac Infarction Injury Score (CIIS) in patients hospitalised for COPD exacerbation. Respir Med 2008;102:1243-7.
  92. Donaldson GC, Hurst JR, Smith CJ, Hubbard RB, Wedzicha JA. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest 2010;137:1091-97.
  93. Halpin DM, Decramer M, Celli B, Kesten S, Leimer I, Tashkin DP. Risk of nonlower respiratory serious adverse events following COPD exacerbations in the 4-year UPLIFT(R) trial. Lung 2011;189:261-8.
  94. Patel AR, Kowlessar BS, Donaldson GC, Mackay AJ, Singh R, George SN, et al. Cardiovascular risk, myocardial injury, and exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013;188:1091-9.
  95. McAllister DA, Maclay JD, Mills NL, Leitch A, Reid P, Carruthers R, et al. Diagnosis of myocardial infarction following hospitalisation for exacerbation of COPD. Eur Respir J 2012;39:1097-103.
  96. Wedzicha JA, Seemungal TA, MacCallum PK, Paul EA, Donaldson GC, Bhowmik A, et al. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb Haemost 2000;84:210-5.
  97. Tillie-Leblond I, Marquette CH, Perez T, Scherpereel A, Zanetti C, Tonnel AB, et al. Pulmonary embolism in patients with unexplained exacerbation of chronic obstructive pulmonary disease: prevalence and risk factors. Ann Intern Med 2006;144:390-96.
  98. Rizkallah J, Man SF, Sin DD. Prevalence of pulmonary embolism in acute exacerbations of COPD: a systematic review and metaanalysis. Chest 2009;135:786-93.
  99. Bertoletti L, Quenet S, Mismetti P, Hernandez L, Martin- Villasclaras JJ, Tolosa C, et al. Clinical presentation and outcome of venous thromboembolism in COPD. Eur Respir J 2012;39:862-8.
  100. Jorgensen NR, Schwarz P, Holme I, Henriksen BM, Petersen LJ, Backer V: The prevalence of osteoporosis in patients with chronic obstructive pulmonary disease: a cross sectional study. Respir Med 2007;101:177-85.
  101. Ohara T, Hirai T, Muro S, Haruna A, Terada K, Kinose D, et al. Relationship between pulmonary emphysema and osteoporosis assessed by CT in patients with COPD. Chest 2008;134:1244-9.
  102. Kiyokawa H, Muro S, Oguma T, Sato S, Tanabe N, Takahashi T, et al. Impact of COPD exacerbations on osteoporosis assessed by chest CT scan. COPD 2012; 9:235-42.
  103. Hanania NA, Mullerova H, Locantore NW, Vestbo J, Watkins ML, Wouters EF, et al. Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort. Am J Respir Crit Care Med 2011;183:604-11.
  104. Quint JK, Baghai-Ravary R, Donaldson GC, Wedzicha JA. Relationship between depression and exacerbations in COPD. Eur Respir J 2008;32:53-60.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.